Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Horm Metab Res ; 31(11): 602-5, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10598827

ABSTRACT

A 58-year-old woman was diagnosed to have pseudohypoparathyroidism (PHP) type II because of the absence of an increase of urinary phosphate secretion, despite a marked increase in urinary cAMP excretion on the Ellsworth-Howard test. We treated the patient with a cyclic-nucleotide phosphodiesterase inhibitor, theophylline, resulting in increased urinary phosphate and cAMP excretions. Dibutyl cAMP administration induced the increase in the urinary phosphate excretion. In this case, the unresponsiveness of the urinary phosphate secretion to cAMP was recovered by a high dose of cAMP or long-term administration of a phosphodiesterase inhibitor. These data imply that cAMP responsiveness to renal tubular phosphate reabsorption should be more strictly elucidated in the patient with PHP type II.


Subject(s)
Phosphates/urine , Phosphodiesterase Inhibitors/administration & dosage , Pseudohypoparathyroidism , Theophylline/administration & dosage , Bucladesine , Calcium/blood , Calcium Channel Blockers , Calcium Compounds , Cyclic AMP/urine , Female , Humans , Lactates , Middle Aged , Nifedipine , Pseudohypoparathyroidism/diagnosis , Pseudohypoparathyroidism/drug therapy , Pseudohypoparathyroidism/urine
2.
Biol Pharm Bull ; 20(1): 104-6, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9013820

ABSTRACT

The enhanced effect of urethane anesthesia on the serum creatine kinase (CPK) level following administration of hypolipidemic agents was examined to develop a convenient experimental screening method for drug-induced myopathy. After oral administration of a hypolipidemic agent to rats, 25% urethane solution was infused intravenously at a very low rate using a microinfusion pump. Blood samples were collected 7 h after drug administration and the risk of myopathy was evaluated based on the CPK level. When bezafibrate (BF), simvastatin (SV), or pravastatin (PV) (50-500 mg/kg) was orally administered under urethane infusion, enhanced elevation of the serum CPK level was observed dose dependently for BF and SV, but not for PV. The elevation of serum CPK was much higher with BF than with SV or PV. In addition, when SV or PV (50-500 mg/kg) was coadministered with 50 mg/kg of BF, there was a striking increase in the serum CPK level as compared with the drug alone. Without urethane infusion, no significant elevation in serum CPK level was observed even at a high dose of these hypolipidemic agents. These phenomena suggest that the urethane anesthesia enhanced the elevation of the serum CPK level following administration of hypolipidemic agents. We propose that this method is a simple and speedy screening test for drug-induced myopathy.


Subject(s)
Hypolipidemic Agents/adverse effects , Muscular Diseases/chemically induced , Anesthesia , Animals , Bezafibrate/adverse effects , Calcium/metabolism , Creatine Kinase/blood , Lovastatin/adverse effects , Lovastatin/analogs & derivatives , Male , Pravastatin/adverse effects , Rats , Rats, Wistar , Simvastatin , Urethane
3.
J Nutr Sci Vitaminol (Tokyo) ; 40(3): 283-8, 1994 Jun.
Article in English | MEDLINE | ID: mdl-7965217

ABSTRACT

The relative proportions (% of total fatty acids) of odd-chain (15:0-29:0) and long-chain (22:0-30:0) saturated fatty acids in phospholipids of biotin-deficient rat lymphocytes were significantly increased as compared with biotin-supplemented rats, and the ratio of unsaturated fatty acids to saturated fatty acids in the former was significantly decreased mainly due to the reduced composition of polyunsaturated fatty acids in the omega-3, omega-6, and omega-9 pathway. The ratio of cis-vaccenic acid to palmitoleic acid in biotin-deficient rats was significantly lower than that in control rats, and was thought to be another important, but previously unreported indicator of biotin deficiency. These changes imply that the elongation and desaturation of unsaturated fatty acids are depressed in lymphocytes of biotin-deficient rats, and may contribute to the associated immunological dysfunction in biotin deficiency through abnormal prostaglandin metabolism and/or cell membrane functions.


Subject(s)
Biotin/deficiency , Fatty Acids/blood , Lymphocytes/metabolism , Animals , Fatty Acids, Monounsaturated/blood , Fatty Acids, Unsaturated/blood , Male , Oleic Acids/blood , Phospholipids/blood , Rats , Rats, Wistar
4.
Biochem Biophys Res Commun ; 199(2): 687-93, 1994 Mar 15.
Article in English | MEDLINE | ID: mdl-8135811

ABSTRACT

Fructose 1,6-bisphosphatase deficiency is an autosomal recessive inherited disorder of gluconeogenesis. We could isolate cDNAs encoding human fructose 1,6-bisphosphatase from normal monocytes, liver and kidney, but not from normal lymphocytes. The cDNAs contained an open reading frame coding for 338 amino acids, and their nucleotide sequences in monocytes and liver were identical. G644C645 nucleotides in this sequence were the same as those of cDNA from HL-60 cells, although our result differed from a previous report (M. El-Maghrabi et al. (1993) J. Biol. Chem. 268, 9466-9472) on an alteration to C644G645 nucleotides in human liver cDNA resulting in a change of Gly-214 to Ala-214 in the enzyme. The Gly-214 (GGC) residue was therefore conserved in the enzymes hitherto isolated from humans and other animals. Analysis of monocytes in seven patients with fructose 1,6-bisphosphatase deficiency showed a DNA fragment with apparent normal size in two sisters but no detectable DNA fragment in the other five patients. Monocytes were thus useful as an alternative source for mRNA from human liver for the molecular analysis of fructose 1,6-bisphosphatase deficiency.


Subject(s)
DNA, Complementary/chemistry , Fructose-1,6-Diphosphatase Deficiency/genetics , Fructose-Bisphosphatase/genetics , Glycine , Kidney/enzymology , Liver/enzymology , Monocytes/enzymology , Point Mutation , Alanine , Amino Acid Sequence , Base Sequence , Cell Line , DNA/genetics , DNA Primers , DNA, Complementary/metabolism , Fructose-Bisphosphatase/biosynthesis , Humans , Lymphocytes/enzymology , Molecular Sequence Data , Oligonucleotides, Antisense , Open Reading Frames , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , Tumor Cells, Cultured
5.
J Inherit Metab Dis ; 17(6): 678-90, 1994.
Article in English | MEDLINE | ID: mdl-7707691

ABSTRACT

Since biotin-deficient (BD) rats are a good animal model for human multiple carboxylase deficiency and have low plasma free carnitine levels, short-chain acylcarnitine profiles in biotin-deficient rats with L-carnitine supplementation (BDC rats) and BD rats were investigated by fast-atom bombardment and tandem mass spectrometry and gas chromatography/mass spectrometry. By the latter method, 3-hydroxyisovalerylcarnitine was identified in BD rats, and showed the greatest accumulation among short-chain acylcarnitines in tissues of BD rats, while the tissue levels of propionic acid were more markedly elevated than those of 3-hydroxyisovaleric acid. The tissue levels of 3-hydroxyisovaleryl-carnitine were significantly lower and those of propionyl-carnitine were somewhat higher in BDC rats than in BD rats, while the tissue levels of propionic acid and 3-hydroxyisovaleric acid in BDC rats were lower than those in BD rats. These changes were more apparent in kidney than in other tissues. The amounts of urinary excretion of acylcarnitines were markedly larger, and those of 3-hydroxyisovaleric acid were somewhat smaller in BDC rats than in BD rats, while those of propionic acid were very low in BD and BDC rats as compared with those of 3-hydroxyisovaleric acid. It seems that the relationship between the concentrations of 3-hydroxyisovalerylcarnitine and those of propionylcarnitine reflects the unique metabolism of the related metabolites in tissues, especially in kidney, which may be influenced by their urinary excretion and the availability of free carnitine. These data in biotin deficiency suggest that carnitine supplementation is possibly beneficial for patients with holocarboxylase synthetase deficiency who respond incompletely to biotin therapy.


Subject(s)
Acetylcarnitine/analysis , Biotin/deficiency , Carnitine/administration & dosage , Animals , Body Fluids/chemistry , Gas Chromatography-Mass Spectrometry , Male , Rats , Rats, Wistar , Spectrometry, Mass, Fast Atom Bombardment
6.
Jpn J Cancer Res ; 83(11): 1216-22, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1483935

ABSTRACT

Here, we describe the effects of quercetin on the induction of thermotolerance as examined by colony forming assay in a cell line derived from human colon carcinoma (COLO320 DM). Cells became resistant to heat treatment at 45 degrees C when they were preheated at 42 degrees C for 1.5 h or at 45 degrees C for 10 min. This induction of thermotolerance was almost completely inhibited by continuous treatment with 100 microM quercetin during the first and second heating sessions, and the interval between. This effect of quercetin was demonstrated to be dose-dependent over a concentration range of 50-200 microM. Quercetin did not increase the thermosensitivity of non-tolerant cells. The presence of quercetin during the first conditioning heating was more effective in inhibiting thermotolerance than its presence during the second heating. Quercetin was also found to inhibit the acquisition of thermotolerance induced by sodium arsenite. Cycloheximide, a nonspecific inhibitor of protein synthesis, did not affect the acquisition of thermotolerance by the same cell line. Quercetin specifically inhibits the synthesis of all heat shock proteins so far reported previously, and this leads to inhibition of the induction of thermotolerance. Such inhibition of thermotolerance by quercetin may improve the efficacy of clinical fractionated hyperthermia.


Subject(s)
Arsenites , Colonic Neoplasms/drug therapy , Heat-Shock Proteins/biosynthesis , Hyperthermia, Induced , Quercetin/pharmacology , Sodium Compounds , Arsenic/pharmacology , Colonic Neoplasms/metabolism , Colonic Neoplasms/therapy , Cycloheximide/pharmacology , Heat-Shock Proteins/antagonists & inhibitors , Humans , Kinetics , RNA Polymerase II/antagonists & inhibitors , Time Factors , Tumor Cells, Cultured/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL